CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement
- PMID: 20653676
- PMCID: PMC2911553
- DOI: 10.1111/j.1365-2125.2010.03698.x
CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement
Abstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT * Genetic polymorphisms of VKORC1 and CYP2C9 are known to influence warfarin dosage. * Recent studies among Caucasians showed that polymorphisms of CYP4F2 also play a role in warfarin pharmacogenetics. * The contribution of CYP4F2 variants to the variability inwarfarin dose requirement in Chinese subjects remains to be investigated. WHAT THIS STUDY ADDS * This research was to study the effect of CYP4F2 variants on warfarin requirements in the Han Chinese population. * This study developed a multiple regression model including CYP2C9, VKORC1 3673G>A, CYP4F2 genotypes and age, weight, combination use of amiodarone which could explain 56.1% of the individual variability in warfarin dose CYP4F2 could explain 4% of the variance in warfarin dose. * We found that one novel genotypic polymorphism 5417G>T for Asp36Tyr, which was identified as an important marker of warfarin resistance, was absent in the Han Chinese population in our study. AIMS The objective of this study was to assess the effect of the CYP4F2 on the daily stable warfarin dose requirement in Han Chinese patients with mechanical heart valve replacement (MHVR). METHODS From March 2007 to November 2008, 222 Han Chinese MHVR patients were recruited in our study. VKORC1 3673G>A, 5417G>T, CYP2C9*3 and CYP4F2 rs2108622 were genotyped by using the polymerase chain reaction restriction fragment length polymorphism method (PCR-RFLP). Polymorphisms of VKORC1 9041G>A were detected by direct sequencing. Multiple linear regression analysis was used to investigate the contribution of CYP4F2. RESULTS The CYP4F2 rs2108622 CT/TT group took a significantly higher stable warfarin dose (3.2 mg day(-1)) than the CC group (2.9 mg day(-1), 95% CI 0.2, 1.0, P= 0.033). The multiple linear regression model included VKORC1 3673G>A, CYP2C9, CYP4F2 genotypes and clinical characteristics. The model could explain 56.1% of the variance in stable warfarin dose in Han Chinese patients with MHVR. CYP4F2 contributed about 4% to the variance in the warfarin dose. There was no variation in the SNPs of VKORC1 5417G>T. CONCLUSION CYP4F2 is a minor significant factor of individual variability in the stable warfarin dose in Han Chinese patients with MHVR. The effect of CYP2C9 and VKORC1 genotypes on variability in the stable warfarin dose had also been confirmed.
Similar articles
-
Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.J Thromb Thrombolysis. 2012 Jul;34(1):120-5. doi: 10.1007/s11239-012-0725-7. J Thromb Thrombolysis. 2012. PMID: 22528326 Clinical Trial.
-
Impact of VKORC1, CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation.BMC Cardiovasc Disord. 2018 May 18;18(1):96. doi: 10.1186/s12872-018-0837-x. BMC Cardiovasc Disord. 2018. PMID: 29776386 Free PMC article.
-
Genetic polymorphisms of VKORC1, CYP2C9, CYP4F2 in Bai, Tibetan Chinese.Pharmazie. 2012 Jan;67(1):69-73. Pharmazie. 2012. PMID: 22393834
-
Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis.Meta Gene. 2016 Jul 5;9:197-209. doi: 10.1016/j.mgene.2016.07.002. eCollection 2016 Sep. Meta Gene. 2016. PMID: 27617219 Free PMC article. Review.
-
The pharmacogenetics of the response to warfarin in Chinese.Br J Clin Pharmacol. 2012 Mar;73(3):340-7. doi: 10.1111/j.1365-2125.2011.04097.x. Br J Clin Pharmacol. 2012. PMID: 22023024 Free PMC article. Review.
Cited by
-
Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.Eur J Clin Pharmacol. 2013 Mar;69(3):395-405. doi: 10.1007/s00228-012-1356-9. Epub 2012 Aug 2. Eur J Clin Pharmacol. 2013. PMID: 22855348
-
Cytochrome P450 oxidoreductase genetic polymorphisms A503V and rs2868177 do not significantly affect warfarin stable dosage in Han-Chinese patients with mechanical heart valve replacement.Eur J Clin Pharmacol. 2013 Oct;69(10):1769-75. doi: 10.1007/s00228-013-1544-2. Epub 2013 Aug 16. Eur J Clin Pharmacol. 2013. PMID: 23949431 Clinical Trial.
-
Personalized approach of medication by indirect anticoagulants tailored to the patient-Russian context: what are the prospects?EPMA J. 2012 Sep 27;3(1):10. doi: 10.1186/1878-5085-3-10. EPMA J. 2012. PMID: 23016735 Free PMC article.
-
Association Between ABCB1 Polymorphism and Stable Warfarin Dose Requirements in Brazilian Patients.Front Pharmacol. 2018 May 23;9:542. doi: 10.3389/fphar.2018.00542. eCollection 2018. Front Pharmacol. 2018. PMID: 29875668 Free PMC article.
-
PharmGKB summary: very important pharmacogene information for CYP4F2.Pharmacogenet Genomics. 2015 Jan;25(1):41-7. doi: 10.1097/FPC.0000000000000100. Pharmacogenet Genomics. 2015. PMID: 25370453 Free PMC article. Review. No abstract available.
References
-
- Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ, Lu MJ, Hung CR, Wei CY, Chen CH, Wu JY, Chen YT. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet. 2005;14:1745–51. - PubMed
-
- Loebstein R, Dvoskin I, Halkin H, Vecsler M, Lubetsky A, Rechavi G, Amariglio N, Cohen Y, Ken-Dror G, Almog S, Gak E. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood. 2007;109:2477–80. - PubMed
-
- Aklillu E, Leong C, Loebstein R, Halkin H, Gak E. VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals. Blood. 2008;111:3903–4. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases